Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > December 18, 2023
Daily News
December 18, 2023
- Terumo’s Next CEO Resolved to Drive Biologics Forward, Fulfill Diverse Demands
December 18, 2023
- Medical Interns Improperly Prescribe, Use GLP-1 Agent for Off-Label Purpose
December 18, 2023
- MHLW to Post Medical Facilities Providing Leqembi Treatment on Website
December 18, 2023
- Japan to Raise Medical Fee by 0.88%, Cut Drug Costs by Around 1% in FY2024
December 18, 2023
- Chuikyo Split on Copay Rate under Elective Care Scheme; Political Decision Likely over 1/2 or 1/4
December 18, 2023
- Eisai CEO Anticipates Leqembi Approval in Europe and China by March
December 18, 2023
- Alecensa Filed for Adjuvant Therapy for ALK-Positive NSCLC: Chugai
December 18, 2023
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…